Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.